Neutralizing antibody response to booster vaccination with the 17d yellow fever vaccine

被引：43

作者：

Hepburn, MJ ^{[1
]}

Kortepeter, MG ^{[1
]}

Pittman, PR ^{[1
]}

Boudreau, EF ^{[1
]}

Mangiafico, JA ^{[1
]}

Buck, PA ^{[1
]}

Norris, SL ^{[1
]}

Anderson, EL ^{[1
]}

机构：

[1] USA, Div Med, Med Res Inst Infect Dis, Ft Detrick, MD 21702 USA

来源：

VACCINE | 2006年 / 24卷 / 15期

关键词：

yellow fever vaccine; booster; neutralizing antibody;

D O I：

10.1016/j.vaccine.2005.12.055

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

A retrospective review was conducted of yellow fever vaccination among laboratory workers receiving annual serologic assessment to determine the initial and long-term response after boosting. Patients were divided into three groups based on pre-vaccination serology: Group 1,1: 10: Group 2, 1:20-1:40 and Group 3, > 1:40. The percent with >= four-fold increase in titers after booster vaccination were: 78% (646/829, Group 1), 65% (79/12 1, Group 2) and 10% (8/79, Group 3) (p < 0.0001). The median times to titer failure (< 1:40) were 798 days (Group 1), 3340 days (Group 2) and 7709 days (Group 3) (p < 0.0001). Pre-vaccination serology influenced the initial and long-term response to yellow fever booster vaccination. Published by Elsevier Ltd.

引用

页码：2843 / 2849

页数：7

共 32 条

[1] Yellow fever vector live-virus vaccines: West Nile virus vaccine development [J].

Arroyo, J ;

Miller, CA ;

Catalan, J ;

Monath, TP .

TRENDS IN MOLECULAR MEDICINE, 2001, 7 (08) :350-354

[2] DENGUE-2 VACCINE - VIROLOGICAL, IMMUNOLOGICAL, AND CLINICAL-RESPONSES OF 6 YELLOW-FEVER IMMUNE RECIPIENTS [J].

BANCROFT, WH ;

TOP, FH ;

ECKELS, KH ;

ANDERSON, JH ;

MCCOWN, JM ;

RUSSELL, PK .

INFECTION AND IMMUNITY, 1981, 31 (02) :698-703

[3]

Barrett Alan D, 2003, Adv Virus Res, V61, P291, DOI 10.1016/S0065-3527(03)61007-9

[4] ANTIGENIC RELATIONSHIPS BETWEEN FLAVIVIRUSES AS DETERMINED BY CROSS-NEUTRALIZATION TESTS WITH POLYCLONAL ANTISERA [J].

CALISHER, CH ;

KARABATSOS, N ;

DALRYMPLE, JM ;

SHOPE, RE ;

PORTERFIELD, JS ;

WESTAWAY, EG ;

BRANDT, WE .

JOURNAL OF GENERAL VIROLOGY, 1989, 70 :37-43

[5] MEASLES ANTIBODY - COMPARISON OF LONG-TERM VACCINATION TITERS, EARLY VACCINATION TITERS AND NATURALLY ACQUIRED-IMMUNITY TO AND BOOSTER EFFECTS ON THE MEASLES-VIRUS [J].

CHRISTENSON, B ;

BOTTIGER, M .

VACCINE, 1994, 12 (02) :129-133

[6]

GROOT H, 1962, B WORLD HEALTH ORGAN, V27, P699

[7] Safety and efficacy of chimeric yellow fever-dengue virus tetravalent vaccine formulations in nonhuman primates [J].

Guirakhoo, F ;

Pugachev, K ;

Zhang, Z ;

Myers, G ;

Levenbook, I ;

Draper, K ;

Lang, J ;

Ocran, S ;

Mitchell, F ;

Parsons, M ;

Brown, N ;

Brandler, S ;

Fournier, C ;

Barrere, B ;

Rizvi, F ;

Travassos, A ;

Nichols, R ;

Trent, D ;

Monath, T .

JOURNAL OF VIROLOGY, 2004, 78 (09) :4761-4775

[8] Commentary: Considerations for use of racial/ethnic classification in etiologic research [J].

Kaufman, JS ;

Cooper, RS .

AMERICAN JOURNAL OF EPIDEMIOLOGY, 2001, 154 (04) :291-298

[9] Viscerotropic and neurotropic disease following vaccination with the 17D yellow fever vaccine, ARILVAX® [J].

Kitchener, S .

VACCINE, 2004, 22 (17-18) :2103-2105

[10] ISOLATION OF A NEWLY RECOGNIZED BUNYAMWERA SEROGROUP VIRUS FROM A FEBRILE HUMAN IN PANAMA [J].

MANGIAFICO, JA ;

SANCHEZ, JL ;

FIGUEIREDO, LT ;

LEDUC, JW ;

PETERS, CJ .

AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 1988, 39 (06) :593-596

← 1 2 3 4 →